vancomycin has been researched along with iclaprim in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hawser, S; Islam, K; Schneider, P | 1 |
| Fritsche, TR; Jones, RN; Sader, HS | 1 |
| Entenza, JM; Giddey, M; Haldimann, A; Hawser, S; Lociuro, S; Moreillon, P | 1 |
| Hawser, S; Islam, K; Laue, H; Lociuro, S; Seguin, A; Valensise, T | 1 |
| Barrow, EW; Barrow, WW; Berlin, KD; Bourne, CR; Bourne, PC; Bunce, RA | 1 |
| Brandt, R; Hadvary, P; Hawser, S; Islam, K; Krievins, D | 1 |
| Corey, GR; Dryden, M; File, TM; Hadvary, P; Huang, DB; Shorr, AF; Torres, A; Wilcox, MH | 1 |
| Amin, F; Corey, GR; Dryden, M; File, TM; Heller, B; Holland, TL; Huang, DB; McLeroth, P; O'Riordan, W; Overcash, JS; Shukla, R; Torres, A; Wilcox, MH | 1 |
| Borghei, A; Corey, GR; Dryden, M; File, TM; Holland, TL; Huang, DB; Lodise, T; McLeroth, P; McManus, A; O'Riordan, W; Oguri, T; Shin, E; Shukla, R; Torres, A; Wilcox, MH | 1 |
| Balser, B; Corey, GR; Desplats, E; Dryden, M; File, TM; Holland, TL; Huang, DB; Lodise, T; O'Riordan, W; Torres, A; Wilcox, MH | 1 |
| Huang, D; Lodise, T; Patel, N | 1 |
| Bryant, AE; Gomi, S; Huang, DB; Katahira, E; Stevens, DL | 1 |
| Balser, B; Corey, GR; Huang, DB; Noviello, S; Scaramucci, A | 1 |
| Charrier, C; Hawser, S; Huang, DB; Le Bras, C; Noviello, S | 1 |
7 trial(s) available for vancomycin and iclaprim
| Article | Year |
|---|---|
Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Pyrimidines; Skin Diseases, Infectious; Staphylococcus aureus; Vancomycin; Young Adult | 2009 |
A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive Pathogens.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cross Infection; Double-Blind Method; Female; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Pneumonia; Pyrimidines; Treatment Outcome; Vancomycin | 2017 |
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Path
Topics: Administration, Intravenous; Adult; Anti-Bacterial Agents; Double-Blind Method; Female; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Pyrimidines; Skin; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2018 |
A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Path
Topics: Administration, Intravenous; Adult; Aged; Female; Gram-Positive Bacteria; Humans; Male; Middle Aged; Pyrimidines; Skin Diseases, Bacterial; Vancomycin | 2018 |
Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Creatinine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Patient Safety; Pyrimidines; Skin Diseases, Bacterial; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pyogenes; Treatment Outcome; Vancomycin | 2018 |
A Pooled Analysis of the Safety and Efficacy of Iclaprim Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Patients With Intravenous Drug Use: Phase 3 REVIVE Studies.
Topics: Administration, Intravenous; Anti-Bacterial Agents; Double-Blind Method; Humans; Pyrimidines; Skin Diseases, Bacterial; Substance Abuse, Intravenous; Treatment Outcome; Vancomycin | 2019 |
The incidence and patient outcomes of ABSSSI by iclaprim MIC values in the phase 3 REVIVE trials for treatment of acute bacterial skin and skin structure infections.
Topics: Acute Disease; Anti-Bacterial Agents; Double-Blind Method; Humans; Incidence; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pyrimidines; Skin; Staphylococcal Skin Infections; Staphylococcus aureus; Vancomycin | 2019 |
7 other study(ies) available for vancomycin and iclaprim
| Article | Year |
|---|---|
Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria.
Topics: Animals; Drug Resistance, Bacterial; Folic Acid Antagonists; Lung; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Pyrimidines; Sepsis; Staphylococcus aureus; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Trimethoprim Resistance; Vancomycin | 2003 |
Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates.
Topics: Anti-Bacterial Agents; Enterococcus faecalis; Europe; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Hospitalization; Humans; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pyrimidines; Staphylococcus aureus; Streptococcus; United States | 2009 |
Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model.
Topics: Animals; Anti-Bacterial Agents; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mutation; Pyrimidines; Rats; Thymidine Kinase; Trimethoprim, Sulfamethoxazole Drug Combination; Vancomycin | 2009 |
In vitro bactericidal activity of iclaprim in human plasma.
Topics: Anti-Bacterial Agents; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Plasma; Pyrimidines; Staphylococcus aureus | 2009 |
Inhibition of antibiotic-resistant Staphylococcus aureus by the broad-spectrum dihydrofolate reductase inhibitor RAB1.
Topics: Anti-Bacterial Agents; Enzyme Inhibitors; Inhibitory Concentration 50; Microbial Sensitivity Tests; Protein Structure, Secondary; Protein Structure, Tertiary; Staphylococcus aureus; Tetrahydrofolate Dehydrogenase | 2010 |
Potential for Cost Saving with Iclaprim Owing to Avoidance of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Cost Savings; Folic Acid Antagonists; Hospitalization; Humans; Pyrimidines; Skin Diseases, Infectious; Vancomycin | 2018 |
The effects of iclaprim on exotoxin production in methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Bacterial Toxins; Biological Assay; Exotoxins; Folic Acid Antagonists; Methicillin-Resistant Staphylococcus aureus; Pyrimidines; Staphylococcus aureus; Trimethoprim; Vancomycin; Virulence Factors | 2019 |